Paper2158355
Naltrexone attenuates self-injurious behavior in mentally retarded subjects.
Kars H and 4 others. Biol Psychiatry, 1990. Cited by 58 papers, by iCite.
Cite this record
ConductScience Library. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Papers, record 2158355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2158355
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Intellectual Disability | Major topic |
| Naltrexone | Major topic |
| Self Mutilation | Major topic |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Brain | |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Down Syndrome | |
| Humans | |
| Institutionalization | |
| Male | |
| Receptors, Opioid |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07641283 | Naltrexone for Nonsuicidal Self-Injury | Results |
Source ClinicalTrials.gov
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 58 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34588931 | Developmental Considerations for the Use of Naltrexone in Children and Adolescents. | J Pediatr Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34588931 | PubMed |
| 30793794 | Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview. | Pharmacotherapy | 2019 | https://conductscience.org/library/papers/30793794 | PubMed |
| 28659987 | The Potential Role of Naltrexone in Borderline Personality Disorder. | Iran J Psychiatry | 2017 | https://conductscience.org/library/papers/28659987 | PubMed |
| 23633366 | Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. | Cochrane Database Syst Rev | 2013 | https://conductscience.org/library/papers/23633366 | PubMed |
| 23251729 | Borderline personality disorder: current drug treatments and future prospects. | Ther Adv Chronic Dis | 2010 | https://conductscience.org/library/papers/23251729 | PubMed |
| 22778191 | Clinical safety of 1500 mg oral naltrexone overdose. | BMJ Case Rep | 2010 | https://conductscience.org/library/papers/22778191 | PubMed |
| 19952075 | The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. | Am J Psychiatry | 2010 | https://conductscience.org/library/papers/19952075 | PubMed |
| 11140779 | Opiate antagonists in children and adolescents. | Eur Child Adolesc Psychiatry | 2000 | https://conductscience.org/library/papers/11140779 | PubMed |
| 8623037 | Recurrent self-injurious behavior in forensic patients. | Psychiatr Q | 1996 | https://conductscience.org/library/papers/8623037 | PubMed |
| 1864831 | Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children. | J Autism Dev Disord | 1991 | https://conductscience.org/library/papers/1864831 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2158355
GET https://conductscience.org/api/papers/v1/2158355/authors